Natera (NASDAQ:NTRA) Stock: Insider John Fesko Sells 302 Shares

Natera, Inc. (NASDAQ:NTRA) insider John Fesko sold 302 shares of the company’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $400.01, for a total value of $120,803.02. Following the completion of the sale, the insider owned 195,276 shares of the company’s stock, valued at $78,112,352.76. This represents a 0.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

John Fesko also recently made the following trade(s):

• On Wednesday, October 28th, John Fesko sold 898 shares of Natera stock. The stock was sold at an average price of $426.34, for a total transaction of $382,853.32.
• On Tuesday, October 27th, John Fesko sold 781 shares of Natera stock. The shares were sold at an average price of $406.00, for a total transaction of $317,086.00.
• On Monday, August 10th, John Fesko sold 6,517 shares of Natera stock. The shares were sold at an average price of $321.53, for a total transaction of $2,095,411.01.

Natera Stock Down 7.0%

Shares of NASDAQ:NTRA opened at $363.76 on Friday. The company has a market capitalization of $52.43 billion, a price-to-earnings ratio of -267.47 and a beta of 1.55. Natera, Inc. has a 52 week low of $181.00 and a 52 week high of $437.41. The firm has a 50 day moving average of $380.81 and a 200 day moving average of $269.30.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, November 5th. The medical research company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.14). Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The company had revenue of $793.98 million for the quarter, compared to the consensus estimate of $707.54 million. During the same period last year, the business posted ($0.64) EPS. The firm’s revenue was up 34.1% compared to the same quarter last year. On average, sell-side analysts expect that Natera, Inc. will post -1.14 EPS for the current year.

Key Headlines Impacting Natera

Here are the key news stories impacting Natera this week:

• Positive Sentiment: Third-quarter revenue rose 34.1% year over year to $794.0 million, exceeding analyst expectations of about $707.5 million. The result points to continued business growth. Natera third-quarter 2026 results
• Positive Sentiment: Medicare coverage for Signatera in hepatocellular carcinoma (HCC) could improve access to the test and support adoption of Natera’s oncology products. Medicare coverage for Signatera in HCC
• Neutral Sentiment: Gross margin was 64.7%, nearly unchanged from 64.9% a year earlier, indicating that strong sales growth came with broadly stable margin performance. Natera third-quarter 2026 results
• Neutral Sentiment: Several executives and insiders sold shares under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards. The sales may attract attention, but their stated purpose and scheduled nature make them less informative about management’s outlook. Natera insider transaction
• Negative Sentiment: Natera reported a quarterly loss of $0.42 per share, wider than analysts’ expected loss of $0.28. The earnings miss likely outweighed the revenue beat and added pressure on the stock. Natera third-quarter 2026 results

Analysts Set New Price Targets

NTRA has been the topic of several analyst reports. Leerink Partners set a $330.00 target price on Natera in a research note on Friday, August 7th. Morgan Stanley raised their price target on shares of Natera from $355.00 to $435.00 and gave the company an “overweight” rating in a report on Monday, October 12th. JPMorgan Chase & Co. lifted their price objective on shares of Natera from $360.00 to $460.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 14th. UBS Group boosted their price objective on shares of Natera from $290.00 to $435.00 and gave the stock a “buy” rating in a research note on Wednesday, September 9th. Finally, Wells Fargo & Company increased their target price on shares of Natera from $220.00 to $284.00 and gave the company an “equal weight” rating in a research report on Friday, August 7th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating, two have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $394.31.

Institutional Investors Weigh In On Natera

Several institutional investors and hedge funds have recently made changes to their positions in the stock. SYM FINANCIAL Corp raised its stake in Natera by 1.7% in the 3rd quarter. SYM FINANCIAL Corp now owns 1,897 shares of the medical research company’s stock worth $784,000 after acquiring an additional 32 shares during the last quarter. Versant Capital Management Inc lifted its position in Natera by 4.6% during the 3rd quarter. Versant Capital Management Inc now owns 815 shares of the medical research company’s stock worth $337,000 after acquiring an additional 36 shares during the period. AlphaCentric Advisors LLC lifted its position in Natera by 3.0% during the 3rd quarter. AlphaCentric Advisors LLC now owns 1,432 shares of the medical research company’s stock worth $592,000 after acquiring an additional 42 shares during the period. VestGen Advisors LLC grew its stake in Natera by 3.1% during the 3rd quarter. VestGen Advisors LLC now owns 1,460 shares of the medical research company’s stock valued at $603,000 after purchasing an additional 44 shares during the last quarter. Finally, Parallel Advisors LLC grew its stake in Natera by 5.5% during the 1st quarter. Parallel Advisors LLC now owns 905 shares of the medical research company’s stock valued at $181,000 after purchasing an additional 47 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Company Profile

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.